In 2010, Ropharma reported net profit of RON10.88 million.
Ropharma said total sales rose 9.4% to RON385.15 million (EUR90.8 million) in 2011, from roughlyRON352 million a year earlier.
Overall revenues increased 8.8% on the year to RON389.8 million, while total spending was up 9.3% to RON377.06 million.
End-December, Ropharma had overall debts of RON297.4 million, up 43% on the year.
According to company estimates, Romania’s retail pharmaceuticals market rose 7.5% on the year to EUR2.2 billion in 2011.
Ropharma is indirectly owned by local businessman Mihai Miron. Cyprus-registered ADD Pharmaceuticals holds a 23.46% stake, while Rimia Investments holds 21.43%. Other shareholders include Arrow Pharmaceuticals with 31.31% and Romania’s privatization authority AVAS with 0.33%.
The company has a share capital of RON29.1 million, split into 291 million shares with a face value of RON0.1.
On the Bucharest bourse Tuesday, Ropharma closed down 0.41% at RON0.6 a share, amid a rising market. (EUR1=RON4.3433)